Clinical trial
MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002…
NCT00496353 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00496353 |
|---|---|
| Title | MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED) |
| Official title | A Phase I/II Dose Escalation and Proof-of-Concept Study of MK2461 in Patients With Advanced Solid Tumors |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasm |
| Intervention type | Drug |
| Interventions | MK2461 |
| Enrollment | 26 |
| Start date | Jun 1, 2007 |
| Primary completion | Oct 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Jul 4, 2007 |
| Last update posted | Mar 31, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: